GCP
CTMX icon

GSA Capital Partners’s CytomX Therapeutics CTMX Stock Holding History

GSA Capital Partners’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$90K Sell
19,140
-62,746
-77% -$318K 0.01% 1568
2025
Q4 		$349K Sell
81,886
-454,088
-85% -$1.72M 0.03% 1083
2025
Q3 		$1.71M Sell
535,974
-94,835
-15% -$214K 0.14% 130
2025
Q2 		$1.43M Sell
630,809
-132,121
-17% -$213K 0.1% 250
2025
Q1 		$485K Buy
762,930
+724,045
+1,862% +$561K 0.04% 827
2024
Q4 		$40K Buy
+38,885
New +$41.8K ﹤0.01% 1542
2024
Q3 		– Sell
-229,093
Closed -$279K – 1660
2024
Q2 		$279K Buy
229,093
+80,526
+54% +$160K 0.02% 1311
2024
Q1 		$324K Buy
148,567
+44,405
+43% +$82K 0.03% 1169
2023
Q4 		$161K Buy
+104,162
New +$137K 0.01% 1362
2023
Q3 		– Sell
-344,169
Closed -$592K – 1558
2023
Q2 		$592K Buy
+344,169
New +$571K 0.06% 641
2021
Q4 		– Sell
-249,146
Closed -$1.27M – 1460
2021
Q3 		$1.27M Buy
+249,146
New +$1.33M 0.13% 194
2021
Q2 		– Sell
-19,093
Closed -$148K – 1355
2021
Q1 		$148K Sell
19,093
-12,761
-40% -$101K 0.02% 959
2020
Q4 		$209K Buy
31,854
+3,603
+13% +$25.7K 0.03% 963
2020
Q3 		$188K Sell
28,251
-12,484
-31% -$92.6K 0.03% 1024
2020
Q2 		$339K Sell
40,735
-20,681
-34% -$192K 0.19% 148
2020
Q1 		$471K Sell
61,416
-55,100
-47% -$384K 0.12% 196
2019
Q4 		$968K Buy
116,516
+38,519
+49% +$260K 0.11% 233
2019
Q3 		$576K Buy
77,997
+12,302
+19% +$121K 0.08% 461
2019
Q2 		$737K Buy
65,695
+30,037
+84% +$315K 0.08% 416
2019
Q1 		$383K Buy
35,658
+958
+3% +$14.2K 0.04% 853
2018
Q4 		$524K Sell
34,700
-200
-0.6% -$2.97K 0.06% 534
2018
Q3 		$646K Sell
34,900
-15,100
-30% -$344K 0.04% 946
2018
Q2 		$1.14M Buy
50,000
+41,167
+466% +$1.05M 0.06% 664
2018
Q1 		$251K Buy
+8,833
New +$252K 0.01% 1384

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GSA Capital Partners's CTMX Position: Q1 2026 in Review

GSA Capital Partners reduced its CytomX Therapeutics (CTMX) stake by 77% in Q1 2026, selling an estimated $318K and leaving 19,140 shares worth $90K. The position accounts for 0.01% of the portfolio, ranked #1568.

GSA Capital Partners first reported a position in CTMX in Q1 2018 and has held it in 24 quarters since. The position peaked at $1.71M in Q3 2025. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • GSA Capital Partners held 19,140 shares of CytomX Therapeutics worth $90K as of Q1 2026.
  • GSA Capital Partners sold 62,746 CytomX Therapeutics shares in Q1 2026, an estimated $318K.
  • CytomX Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q1 2026, its #1568 holding.
  • GSA Capital Partners first reported a position in CytomX Therapeutics in Q1 2018 and has held it in 24 quarters since.
  • GSA Capital Partners's CytomX Therapeutics position peaked at $1.71M in Q3 2025.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.